Clinical Molecular Imaging of Pulmonary CXCR4 Expression to Predict Outcome of Pirfenidone Treatment in IPF.
Sign Up to like & getrecommendations! Published in 2020 at "Chest"
DOI: 10.1016/j.chest.2020.08.2043
Abstract: BACKGROUND IPF is a progressive disease for which two antifibrotic drugs have recently been approved, however there is an unmet need to predict responses to antifibrotic treatment, such as pirfenidone. Recent data suggested that up-regulated… read more here.
Keywords: pulmonary cxcr4; cxcr4 expression; treatment; pirfenidone ... See more keywords